Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1261 to 1275 of 2107 results for technology appraisal

  1. Bevacizumab for the first-line treatment of metastatic breast cancer (TA147)

    This appraisal has been updated and replaced by NICE technology appraisal 214.

    Withdrawn guidance

  2. Tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis (HTG648)

    Evidence-based recommendations on tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis. This involves inserting a catheter under the skin in the abdomen to drain excess fluid when needed, at home or in community care. The aim is to reduce the need for hospital admissions and improve quality of life.

    HealthTech guidance
    Published
    23 November 2022
    View recommendations

    Sections for HTG648

  3. The clinical and cost effectiveness of pegylated interferon alpha 2a and alpha 2b for hepatitis C (TA14)

    This guidance has been replaced by NICE technology appraisal guidance 75.

    Withdrawn guidance

  4. Interstitial cystitis: oral pentosan polysulfate sodium (ESUOM43)

    This guidance has been updated and replaced by NICE technology appraisal guidance 610.

    Withdrawn advice

  5. Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene (TA296)

    This guideance has been updated and replaced by NICE technology appraisal guidance 422.

    Withdrawn guidance

  6. Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (TA360)

    This guidance has been updated and replaced by NICE technology appraisal guidance 476.

    Withdrawn guidance

  7. Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446)

    This guidance has been updated and replaced by NICE technology appraisal guidance 524.

    Withdrawn guidance

  8. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (TA301)

    This guidance has been updated and replaced by NICE technology appraisal guidance 953.    

    Withdrawn guidance

  9. Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) (TA987)

    This guidance has been updated and replaced by NICE's technology appraisal guidance 1159 (TA1159).

    Withdrawn guidance

  10. TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

    Withdrawn advice

  11. SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

    Withdrawn advice

  12. The clinical effectiveness and cost effectiveness of insulin pump therapy (TA57)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 151.

    Withdrawn guidance

  13. Cetuximab for the treatment of metastatic colorectal cancer following failure of oxaliplatin-containing chemotherapy (TA150)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 242.

    Withdrawn guidance

  14. Borderline personality disorder: recognition and management (CG78)

    This guideline covers recognising and managing borderline personality disorder. It aims to help people with borderline personality disorder to manage feelings of distress, anxiety, worthlessness and anger, and to maintain stable and close relationships with others.

    Clinical guideline
    Published
    28 January 2009
    View recommendations

    Sections for CG78

  15. Lumasiran for treating primary hyperoxaluria type 1 (HST25)

    Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.

    Highly specialised technologies guidance
    Published
    19 April 2023
    View recommendations

    Sections for HST25